EGFR and dermatological toxicity: The incidence of capecitabine-related HFS (11/13 articles) and EGFR inhibitor-related skin toxicities (1/1 article) tended to be higher with the addition of ICIs.<h4>Conclusions</h4>While ICIs have substantially improved survival outcomes, their immunomodulatory effects may amplify drug-specific dermatologic toxicities when used in combination regimens.